Overexpression of AIM2 through STAT1/NF-κB pathway is associated with cancer progression, radioresistance, and increased PD-L1 expression, thus upregulated AIM2 predicting favorable response for ICI therapy [345]. The gene discussed is AIM2; the disease is cancer.